Another Chance at Life
Molecular profiling of long-term survivor Roy Vinke’s tumor and found a mismatch repair deficiency, which changed his treatment.
Molecular profiling of long-term survivor Roy Vinke’s tumor and found a mismatch repair deficiency, which changed his treatment.
Drs. Avery Posey and Dannielle Engle are the inaugural winners of the Lustgarten Foundation-AACR Career Development Awards for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg and John Lewis.
Read the highlights of Saturday’s sessions about tumor microenvironment, recurrence, and treatment resistance, at the AACR pancreatic cancer conference.
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
The approach is called chimeric antigen receptor (CAR) T cell therapy, which uses specially modified immune cells to find and destroy cancerous cells. A version of CAR T cell therapy was recently endorsed by an advisory committee to the Food and Drug Administration for treatment of advanced leukemia. Despite great success against certain types of…
Caris is providing clinical trial enrollment services to identify potential trial candidates based on biomarker expression results and facilitate communication between treating physicians and study investigators. The Lustgarten Foundation is a sponsor of the study for pancreatic cancer patients in support of its mission to advance scientific and medical research related to the diagnosis, treatment…
Now, Salk scientists have pinned down how signals from this microenvironment encourage pancreatic tumors to grow by altering their metabolism. Blocking the pathways involved, they reported in Proceedings of the National Academy of Sciences the week of January 16, 2017, can slow the growth of a pancreatic cancer. “Pancreatic cancer is a deadly disease and…